Safety and efficacy of intravenous bimagrumab in inclusion body myositis

Lancet published the latest results to Bimagrumab from Novartis in the RESILIENT study.

Between Sept 26, 2013, and Jan 6, 2016, 251 participants were enrolled to the study, of whom 63 were assigned to each bimagrumab group and 62 were allocated to the placebo group.

For more Details visit Lancet

Clinical Trials

News about Myositis

By Liz

Until those day, was my kiss of death been stronger than those of the devil. I like to ride through hellfire with him ,when I come out victorious afterwards. I'm strong and proud rheumatoid arthritis warrior

Följ mig, tack!

Liz - Fotoblogg

3 replies on “Safety and efficacy of intravenous bimagrumab in inclusion body myositis”

Hello Hanna,

no Bimagrumab is in clinical development at Novartis and is not yet available on market. The antibody was developed by MorphoSys in Munich.

Activin type II receptors are intended for the treatment of muscle disorders associated with muscle atrophy.


Comments are closed.